Welcome to our dedicated page for AN2 Therapeutics news (Ticker: ANTX), a resource for investors and traders seeking the latest updates and insights on AN2 Therapeutics stock.
AN2 Therapeutics, Inc. reports clinical-stage biopharmaceutical developments tied to novel small-molecule therapeutics derived from its boron chemistry platform. Company updates center on infectious-disease programs such as Chagas disease, NTM lung disease caused by Mycobacterium abscessus and melioidosis, along with oncology, hematologic-disease and other research programs.
Recurring ANTX news includes clinical and regulatory updates for candidates such as epetraborole and AN2-502998, investigator-initiated trial activity, operating and financial results, material agreements, governance matters and investor conference participation.
AN2 Therapeutics (Nasdaq: ANTX) reported first quarter 2026 results and multiple clinical milestones. R&D expenses were $6.7 million, G&A $3.8 million, and net loss $10.0 million. Cash, cash equivalents and investments totaled $85.3 million, including $40.0 million in March 2026 private placement proceeds.
The company advanced oral epetraborole toward a Phase 2 trial in polycythemia vera, supported a Phase 2 investigator-initiated trial in M. abscessus lung disease, progressed AN2-502998 for chronic Chagas disease, and declared an ENPP1 candidate for solid tumors. AN2 projects cash runway into 2029.
AN2 Therapeutics (Nasdaq: ANTX) announced management will participate at the 2026 Stifel Virtual Targeted Oncology Forum. Eric Easom, co-founder and CEO, will appear in a fireside chat on May 19, 2026 at 4:00 PM ET, and management is available for 1x1 meetings. A live webcast and an archived replay (available for at least 30 days) will be accessible on the company's Investors website.
AN2 Therapeutics (Nasdaq: ANTX) announced initiation of a Phase 2 investigator-initiated trial of epetraborole for Mycobacterium abscessus lung disease. The 84-patient, multicenter, randomized, double-blind study is led by Dr. Kevin Winthrop at OHSU across an estimated 10–15 U.S. sites.
Patient screening is underway and topline data are planned for late 2027. Epetraborole is an oral inhibitor of leucyl-tRNA synthetase being evaluated for safety, efficacy, and pharmacokinetics.
AN2 Therapeutics (Nasdaq: ANTX) reported Q4 and full-year 2025 results and program updates. Key clinical milestones include planned Phase 2 for oral epetraborole in polycythemia vera starting 3Q26 with data possible from 4Q26, an FDA-cleared Phase 2 investigator-initiated trial in M. abscessus (enrollment 1Q26, topline late 2027), and nearing Phase 1 readout for AN2-502998 in Chagas (initial data expected 1Q26). The company plans two oncology candidates in 2026 and completed a ~$40M private placement, projecting runway into 2029.
AN2 Therapeutics (Nasdaq: ANTX) entered a securities purchase agreement for a private placement expected to raise approximately $40 million gross, before placement agent fees and expenses. The company will sell 8,245,611 common shares at $2.85 each and offer pre-funded warrants for up to 5,789,493 shares at $2.84999 each.
The pre-funded warrants carry a $0.00001 exercise price and are exercisable immediately subject to ownership limits. The offering is expected to close on March 10, 2026, subject to customary conditions, and AN2 will file a registration statement to register resale of the securities.
AN2 Therapeutics (Nasdaq: ANTX) will advance oral epetraborole into a Phase 2 proof-of-concept study for phlebotomy-dependent polycythemia vera, targeting initiation in 3Q26 with potential data readouts as early as 4Q26 and continuing through 2027.
Company observations include consistent, early and sustained hematocrit reductions across healthy volunteers and non-PV patients, durable effects in nine-month non-human primate studies, a likely globin-directed mechanism, and generally favorable tolerability at anticipated PV doses. Regulatory clearance and enrollment progress remain prerequisites to start and public updates.
AN2 Therapeutics (Nasdaq: ANTX) announced that Eric Easom, co-founder, chairman, president and CEO, will appear in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026 at 3:40 PM ET. A live webcast will be available on the company investor site and an archived replay will be accessible for at least 30 days following the presentation.
AN2 Therapeutics (NASDAQ: ANTX) announced FDA clearance of an IND enabling a 90-patient investigator-initiated trial (IIT) of oral epetraborole in Mycobacterium abscessus lung disease. The multicenter, randomized, double-blind, placebo-controlled study will be led by Dr. Kevin Winthrop and run across an estimated 10–15 U.S. sites, with patient enrollment expected to begin in 1Q 2026. The program targets a high unmet need: there are currently no FDA-approved therapeutics for M. abscessus and the pathogen is resistant to most oral antibiotics. AN2 cites an estimated 120,000–150,000 U.S. patients with NTM lung disease, with 10–15% due to M. abscessus; positive IIT results could establish human proof of concept and inform a subsequent pivotal trial.
AN2 Therapeutics (Nasdaq: ANTX) reported Q3 2025 results and pipeline progress on November 12, 2025. Key corporate highlights include a Phase 1 first‑in‑human trial of oral AN2-502998 for chronic Chagas disease with Phase 1 data expected in Q1 2026 and Phase 2 planning in 2026. The company expects two boron‑based oncology programs to enter development in early and mid‑2026. AN2 announced a collaboration with GSK on boron LeuRS inhibitors for TB and received a third year of funding from the Gates Foundation. Financials: Q3 R&D $7.0M, G&A $3.0M, net loss $9.4M, and $65.1M cash and investments as of September 30, 2025, with projected runway into 2028.
AN2 Therapeutics (Nasdaq: ANTX) announced a collaboration with GSK to develop boron-based LeuRS inhibitors targeting tuberculosis, announced November 10, 2025.
The Gates Foundation will provide a third year of funding to support AN2’s role in the collaboration. AN2 highlighted its boron chemistry platform and cited LeuRS as a validated target underlying epetraborole, ganfeborole and the FDA-approved tavaborole.
AN2 and GSK said the partnership aims to advance novel small-molecule TB therapies, with AN2 contributing boron-chemistry expertise and GSK contributing Global Health R&D resources.